These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36428792)

  • 1. The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments.
    Ferro A; Sepulcri M; Schiavon M; Scagliori E; Mancin E; Lunardi F; Gennaro G; Frega S; Dal Maso A; Bonanno L; Paronetto C; Caumo F; Calabrese F; Rea F; Guarneri V; Pasello G
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
    Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
    Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
    Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
    ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience.
    Borghetti P; Volpi G; Facheris G; Cossali G; Mataj E; La Mattina S; Singh N; Imbrescia J; Bonù ML; Tomasini D; Vitali P; Greco D; Bezzi M; Melotti F; Benvenuti M; Borghesi A; Grisanti S; Buglione di Monale E Bastia M
    Front Oncol; 2023; 13():1208204. PubMed ID: 37469420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.
    Ouwens M; Darilay A; Zhang Y; Mukhopadhyay P; Mann H; Ryan J; Dennis PA
    Curr Ther Res Clin Exp; 2021; 95():100640. PubMed ID: 34484473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP).
    Raez LE; Arrieta O; Chamorro DF; Soberanis-Piña PD; Corrales L; Martín C; Cuello M; Samtani S; Recondo G; Mas L; Zatarain-Barrón ZL; Ruíz-Patiño A; García-Robledo JE; Ordoñez-Reyes C; Jaller E; Dickson F; Rojas L; Rolfo C; Rosell R; Cardona AF
    Front Oncol; 2022; 12():904800. PubMed ID: 35903685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
    Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
    Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up.
    Abbas MN; Ayoola A; Padman S; Kumar R; Leung J; Ullah S; Koczwara B; Sukumaran S; Kichenadasse G; Roy A; Richards AM; Bowden JJ; Karapetis CS
    J Thorac Dis; 2019 Oct; 11(10):4241-4248. PubMed ID: 31737309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
    Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
    Kim ES; Putnam JB; Komaki R; Walsh GL; Ro JY; Shin HJ; Truong M; Moon H; Swisher SG; Fossella FV; Khuri FR; Hong WK; Shin DM
    Lung Cancer; 2004 Jun; 44(3):369-79. PubMed ID: 15140551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
    Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
    Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.
    Zhou Q; Chen M; Wu G; Chang JH; Jiang O; Cui JW; Han G; Lin Q; Fang J; Chen GY; Wu YL
    Transl Lung Cancer Res; 2020 Oct; 9(5):2008-2015. PubMed ID: 33209620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.